<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355667</url>
  </required_header>
  <id_info>
    <org_study_id>H18-Junkanki(seishu)-ippan-046</org_study_id>
    <nct_id>NCT00355667</nct_id>
  </id_info>
  <brief_title>Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure</brief_title>
  <acronym>J-MELODIC</acronym>
  <official_title>Japanese Multicenter Evaluation of Long- Versus Short-acting Diuretics in Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyogo College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hyogo College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare therapeutic effects of furosemide, a short-acting
      loop diuretic, and azosemide, a long-acting one, in patients with heart failure, and to test
      our hypothesis that long-acting diuretics are superior to short-acting types in heart
      failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mortality and morbidity of heart failure are still high despite emerging evidences that
      have shown beneficial effects of ACE inhibitor, beta-blocker, ARB, and aldosterone receptor
      antagonist. Diuretics are the most prescribed in heart failure patients in attenuating
      symptoms due to fluid retention, and diuretics are recommended as essential medicines in
      patients with heart failure symptoms and/or fluid retention. However, the effects of a
      long-term administration of diuretics on morbidity and mortality have not been adequately
      assessed in the prospective clinical study, and the retrospective analysis did not
      necessarily indicate the diuretic-induced improvement of mortality. McCurley et al
      demonstrated the adverse effects of furosemide in a tachycardia-induced heart failure model
      (J Am Coll Cardiol 2004; 44: 1301-1307). Yoshida et al. demonstrated that the administration
      of furosemide did not improve mortality rate, while the administration of azosemide, a
      long-acting loop diuretic, improved mortality rate in a hypertensive heart failure model
      (Cardiovasc Res 2005; 68: 118-127). If the effects on mortality and/or morbidity of heart
      failure patients are different among classes of diuretics, we should choose a class to
      provide better prognosis. Thus, we designed a multicenter prospective study, J-Melodic
      (Japanese Multicenter Evaluation of LOng- versus short-acting Diuretics In Congestive heart
      failure) to obtain a clinical evidence about the effects of diuretics in heart failure.

      Comparison: Congestive heart failure patients matched with the following conditions will be
      recruited: (1) clinical diagnosis of heart failure based on a slight modification of the
      Framingham criteria within 6 months before the entry, (2) twenty years or older, (3) NYHA II
      or III, (4) loop diuretic(s) is (are) administered currently, (5) no change in baseline
      therapy and symptoms of heart failure within a month. After screening for eligibility and
      obtaining written informed consent, patients will be randomized to either azosemide or
      furosemide treatment in a 1:1 ratio. In any arms, patients are treated with standard therapy
      including digitalis, mineralocorticoid receptor blockers, ACE inhibitors, ARB, beta-blockers,
      and calcium channel blockers. Patients discontinued taking previous loop diuretic(s) and were
      directly rolled over to one of the two arms with either azosemide 30-60 mg/day or furosemide
      20-40 mg/day, without a placebo run-in period. The dose of each diuretic will be
      appropriately adjusted according to symptoms of each patient, and patients will be maintained
      for the rest of the study. Thereafter, patients are reviewed every 2 to 8 weeks. The planned
      minimum follow-up period for each patient is 2 years, and electrocardiography, chest X-ray
      and blood sample will be conducted at the study entry and every 12 months after the
      randomization.

      The primary outcome is a composite of cardiovascular death and unplanned admission to
      hospital for congestive heart failure. The secondary outcomes are listed as follows: all
      cause mortality; worsening of the symptoms [that is defined by either a decrease by (1) 1
      Mets in the SAS questionnaire score or an increase by (2) I class in the NYHA functional
      class for at least 3 months as compared with the baseline]; an increase in brain natriuretic
      peptide (BNP) by more than 30% of the value at the randomization in patients with BNP less
      than 200 pg/ml at the randomization; unplanned admission to hospital for congestive heart
      failure, or a need for modification of the treatment for heart failure (changes in oral
      medicine for at least one month or addition of intravenous drug(s) for at least 4 hours).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a composite of cardiovascular death and unplanned admission to hospital for congestive heart failure</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worsening of the symptoms (that is defined by either a decrease by &lt;1 Mets in the SAS questionnaire score or an increase by &gt;I class in the NYHA functional class for at least 3 months as compared with the baseline)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>an increase in brain natriuretic peptide (BNP) by &gt; 30% of the value at the randomization in patients with BNP &lt; 200 pg/ml at the randomization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a need for modification of the treatment for heart failure (changes in oral medicine for at least one month or addition of intravenous drug(s) for at least 4 hours)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>furosemide</intervention_name>
    <description>Patients with chronic heart failure receive furosemide and other standard treatment/</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azosemide</intervention_name>
    <description>Patients with chronic heart failure receive azosemide and other standard treatment.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Daiart</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of heart failure based on a slight modification of the Framingham
             criteria as previously described within 6 months before the entry

          -  Current status of heart failure is NYHA II or III.

          -  Currently, loop diuretic(s) is (are) administered.

          -  No change in baseline therapy and symptoms of heart failure within a month

        Exclusion Criteria:

          -  Current symptomatic hypotension

          -  Hypertension that has not been controlled to the satisfaction of the investigator

          -  Hemodynamically significant (in the investigators opinion) LV outflow tract
             obstruction (due to either aortic stenosis or ventricular hypertrophy)

          -  Acute coronary syndrome

          -  Primary pulmonary hypertension or pulmonary hypertension not due to LV dysfunction

          -  Serious cerebrovascular disease

          -  Acute myocardial infarction within the last 3 months

          -  Patients who require intravenous inotropes

          -  Cerebrovascular accident within the last 3 months

          -  Percutaneous coronary intervention or open heart surgery within the last 3 months

          -  On the waiting list for percutaneous coronary intervention or open heart surgery

          -  Serum creatinine &gt; 2.5 mg/dl

          -  Serious liver disease

          -  Any change in cardiovascular drug therapy within a month prior to randomization

          -  History of chronic obstructive pulmonary disease or restrictive lung disease

          -  Diabetes mellitus that has not been well controlled (fasting blood glucose&gt;200
             mg/dl„ÄÅHbA1c &gt; 8%)

          -  Any life-threatening acute disease

          -  Patients with implantable cardiac defibrillator

          -  Other diseases likely to cause death or serious disability during the period of the
             study

          -  Patients unable to walk without personal aid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tohru Masuyama, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Division, Hyogo College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital of Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishio M, Ohtani T, Hori M, Miwa T, Masuyama T. Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res. 2005 Oct 1;68(1):118-27.</citation>
    <PMID>16002057</PMID>
  </reference>
  <reference>
    <citation>J-MELODIC Program Committee. Rationale and design of a randomized trial to assess the effects of diuretics in heart failure: Japanese Multicenter Evaluation of Long- vs Short-Acting Diuretics in Congestive Heart Failure (J-MELODIC). Circ J. 2007 Jul;71(7):1137-40.</citation>
    <PMID>17587724</PMID>
  </reference>
  <results_reference>
    <citation>Masuyama T, Tsujino T, Origasa H, Yamamoto K, Akasaka T, Hirano Y, Ohte N, Daimon T, Nakatani S, Ito H. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J. 2012;76(4):833-42.</citation>
    <PMID>22451450</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2006</study_first_submitted>
  <study_first_submitted_qc>July 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2006</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hyogo College of Medicine</investigator_affiliation>
    <investigator_full_name>Tohru Masuyama</investigator_full_name>
    <investigator_title>Cardiovascular Division, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>diuretics</keyword>
  <keyword>furosemide</keyword>
  <keyword>azosemide</keyword>
  <keyword>congestive heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Azosemide</mesh_term>
    <mesh_term>Sulfanilamides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

